Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
WTI Crude Oil Prices Rise Amid Iran Conflict Uncertainty 
Yen Weakens After Intervention Spike as Dollar Stabilizes Amid Global Tensions 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Trump Rejects Iran Proposal as Tensions Persist Amid Fragile Ceasefire 
Gold Prices Hold Steady as Iran War and Interest Rate Outlook Weigh on Markets 
US Stock Futures Rise as S&P 500 and Nasdaq Hit Record Highs Amid Earnings Optimism and Iran Tensions 
Oil Prices Ease but Remain Set for Strong April Gains Amid Middle East Tensions 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Oil Prices Fall as Iran Proposes New Deal Amid Ongoing U.S. Tensions 
Google Secures Pentagon AI Deal for Classified Projects 
Merck & Co Inc. gets the green light from the Japanese health ministry for its COVID-19 anti-viral pill. The health officials recommended the approval of the said medicine late last week.
The approval of the Merck coronavirus pill is said to be part of the country’s Prime Minister Fumio Kishida’s plan to introduce and distribute new treatments by the end of the year as the growing cases of Omicron variant infection is becoming a very serious concern.
According to Inquirer.net, the committee’s decision has led to the shipments of around 200,000 doses starting this weekend. This is just the preparation and start of the deliveries as per the announcement of the country’s prime minister.
“I am convinced the distribution of this drug is a major step forward for our nation’s COVID–19 handling,” Shigeyuki Goto, Japan’s health minister, told the press after the announcement of the panel’s approval of Merck’s COVID-19 treatment pill.
He added that some of the country’s pharmacies and medical institutions are expected to begin receiving the medicine as early as next Monday. Moreover, it was said that Japan is really laying bets on oral treatments to prevent cases of severe infections and deaths should a sixth wave of the pandemic arise.
Based on the report, Japan agreed to pay $1.2 billion to Merck and its partner Ridgeback Biotherapeutics for the shipment of 1.6 million courses of molnupiravir. PM Kishida also said last week, the government signed a deal for two million doses of another anti-viral treatment pill and this was developed by Pfizer.
In the U.S., health regulators also authorized the use of the Merck pill for some high-risk adult patients. Many countries are now rushing to purchase the said Merck’s molnupiravir due to promising results during trials.
“As a single oral medicine that can be taken at home, early treatment with molnupiravir significantly reduced the risk of hospitalization or death in patients at high risk for progressing to severe COVID-19,” Merck research laboratories president, Dr. Dean Y. Li, said in a press release. “Importantly for patients, there were markedly fewer deaths among those taking molnupiravir in our clinical study and we believe that it will be a critical addition to the measures available to help curb the impact of COVID-19 on patients, healthcare systems, and public health in Japan.”
